Jan 20, 2022Coeptis Therapeutics Establishes Scientific Advisory Board to Advance Cell Therapy Product DevelopmentNewly formed Scientific Advisory Board includes three members from the prestigious Karolinska Institutet (KI)
Coeptis Therapeutics, Inc. (OTC PINK: COEP), a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announces the formation of its Scientific Advisory Board...
Aug 19, 2021Coeptis Therapeutics Partners with VyGen-Bio, Inc. to Co-develop Two Assets Designed to Improve the Treatment of CD38-Related CancersTechnologies include CD38-GEAR-NK, a cell therapy technology, and CD38-Diagnostic, an in vitro diagnostic
Coeptis Therapeutics, Inc. (OTC PINK: COEP), a pharmaceutical company focused on the development of innovative technologies designed to disrupt conventional treatment paradigms and improve patient...
Jul 9, 2021New Corporate Name and Updated Stock Ticker Symbol Highlight Company's Brand Transformation
Vinings Holdings, Inc. (OTC PINK: NDYN), today announced that it is changing its corporate name to "Coeptis Therapeutics, Inc." and updating its ticker symbol to "COEP" effective Monday, July 12,...
May 18, 2021Coeptis Pharmaceuticals Enters into Exclusive Option Agreements with VyGen-Bio to Co-develop Technologies Designed to Improve the Treatment of CD38-Related CancersTechnologies being developed from VyGen-Bio's Gene-Edited Antibody Resistant NK (GEAR-NK) Platform
Coeptis Pharmaceuticals, Inc., a wholly-owned subsidiary of Vinings Holdings Inc. (OTC PINK: NDYN), today announced entry into two separate exclusive option agreements with VyGen-Bio, Inc., a...